AbbVie, Nimble

AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish
Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions from investors. AbbVie announced a $200 million deal to acquire Nimble Therapeutics,
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
AbbVie To Acquire Nimble Therapeutics For $200 Mln In Cash
Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along
AbbVie buys Roche spinout Nimble Therapeutics for $200M
AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble Therapeutics,
AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline
AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio.
AbbVie Acquires Nimble Therapeutics in $200 Million Deal to Strengthen Immunology Pipeline
AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for psor
AbbVie buying Wisconsin biotech company Nimble Therapeutics for $200 million
AbbVie Inc. said Friday it’s buying Nimble Therapeutics of Madison, Wisconsin, for $200 million. North Chicago-based AbbVie (NYSE: ABBV) said Nimble is working on creating an oral peptide “for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
The Business Journals2d
AbbVie to buy Madison pharmaceutical tech firm for $200 million
Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble Therapeutics Inc. for $200 million in cash.
BioPharma Dive1d
AbbVie to acquire Roche spinout Nimble in immune drug deal
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
Business Insider1d
AbbVie to acquire Nimble Therapeutics for $200M cash at closing
AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...
Crain's Chicago Business1d
AbbVie to acquire Wisconsin biopharma for $200 million
Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...
The Pharma Letter1d
AbbVie nabs autoimmune diseases specialist Nimble
US drugmaker AbbVie is to acquire Nimble Therapeutics, a USA-based Roche spinout developing oral peptide treatments in the ...